<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39337989</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>Avoided and Avoidable Deaths with the Use of COVID-19 Convalescent Plasma in Italy during the First Two Years of Pandemic.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1207</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life14091207</ELocationID><Abstract><AbstractText>Italy was the first western country to be hit by the COVID-19 pandemic and has suffered nearly 200,000 deaths so far during the four years of the pandemic. In March 2020, Italy first deployed COVID-19 convalescent plasma (CCP) to treat hospitalized patients. Despite this initial effort, the proportion of COVID-19 patients treated with CCP during the first two years of the pandemic (2020-2021) was very low (approximately 2% of individuals hospitalized for COVID-19). In this study, we estimated the number of actual inpatient lives saved by CCP treatment in Italy using national mortality data, and CCP mortality reduction data from meta-analyses of randomized controlled trials and real-world data. We also estimated the potential number of lives saved if CCP had been deployed to 100% of hospitalized patients or used in 15% to 75% of outpatients. According to these models, CCP usage in 2020-2021 saved between 385-1304 lives, but this number would have increased to 17,751-60,079 if 100% of inpatients had been transfused with CCP. Similarly, broader (15-75%) usage in outpatients could have prevented 21,187-190,689 hospitalizations (desaturating hospitals) and 6144-81,926 deaths. These data have important implications for convalescent plasma use in future infectious disease emergencies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Franchini</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8795-0580</Identifier><AffiliationInfo><Affiliation>Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, 46100 Mantua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casadevall</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9402-9167</Identifier><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragotakes</LastName><ForeName>Quigly</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-4068-5828</Identifier><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Focosi</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8811-195X</Identifier><AffiliationInfo><Affiliation>North-Western Tuscany Blood Bank, Pisa University Hospital, Via Paradisa 2, 56124 Pisa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 convalescent plasma (CCP)</Keyword><Keyword MajorTopicYN="N">absolute risk reduction (ARR)</Keyword><Keyword MajorTopicYN="N">relative risk reduction (RRR)</Keyword></KeywordList><CoiStatement>The authors declare they have no conflicts of interest related to this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337989</ArticleId><ArticleId IdType="pmc">PMC11433499</ArticleId><ArticleId IdType="doi">10.3390/life14091207</ArticleId><ArticleId IdType="pii">life14091207</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus Disease (COVID-19) Pandemic.  [(accessed on 5 February 2024)].  Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019.</Citation></Reference><Reference><Citation>Shen C., Wang Z., Zhao F., Yang Y., Li J., Yuan J., Wang F., Li D., Yang M., Xing L., et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020;323:1582–1589. doi: 10.1001/jama.2020.4783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.4783</ArticleId><ArticleId IdType="pmc">PMC7101507</ArticleId><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>Perotti C., Baldanti F., Bruno R., Del Fante C., Seminari E., Casari S., Percivalle E., Glingani C., Musella V., Belliato M., et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020;105:2834–2840. doi: 10.3324/haematol.2020.261784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2020.261784</ArticleId><ArticleId IdType="pmc">PMC7716363</ArticleId><ArticleId IdType="pubmed">33256382</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner M.J., Wright R.S., Fairweather D., Senefeld J.W., Bruno K.A., Klassen S.A., Carter R.E., Klompas A.M., Wiggins C.C., Shepherd J.R., et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J. Clin. Investig. 2020;130:4791–4797. doi: 10.1172/JCI140200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140200</ArticleId><ArticleId IdType="pmc">PMC7456238</ArticleId><ArticleId IdType="pubmed">32525844</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini M., Cruciani M., Casadevall A., Joyner M.J., Senefeld J.W., Sullivan D.J., Zani M., Focosi D. Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. Transfusion. 2024;64:388–399. doi: 10.1111/trf.17701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.17701</ArticleId><ArticleId IdType="pubmed">38156374</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld J.W., Gorman E.K., Johnson P.W., Moir M.E., Klassen S.A., Carter R.E., Paneth N.S., Sullivan D.J., Morkeberg O.H., Wright R.S., et al. Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis. Mayo Clin. Proc. Innov. Qual. Outcomes. 2023;7:499–513. doi: 10.1016/j.mayocpiqo.2023.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocpiqo.2023.09.001</ArticleId><ArticleId IdType="pmc">PMC10582279</ArticleId><ArticleId IdType="pubmed">37859995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan D.J., Focosi D., Hanley D.F., Cruciani M., Franchini M., Ou J., Casadevall A., Paneth N. Outpatient randomized controlled trials to reduce COVID-19 hospitalization: Systematic review and meta-analysis. J. Med. Virol. 2023;95:e29310. doi: 10.1002/jmv.29310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29310</ArticleId><ArticleId IdType="pmc">PMC10754263</ArticleId><ArticleId IdType="pubmed">38105461</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini M., Cruciani M., Mengoli C., Casadevall A., Glingani C., Joyner M.J., Pirofski L.A., Senefeld J.W., Shoham S., Sullivan D.J., et al. Convalescent plasma and predictors of mortality among hospitalized COVID-19 patients: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2024 doi: 10.1016/j.cmi.2024.07.020. epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2024.07.020</ArticleId><ArticleId IdType="pubmed">39067517</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld J.W., Franchini M., Mengoli C., Cruciani M., Zani M., Gorman E.K., Focosi D., Casadevall A., Joyner M.J. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw. Open. 2023;6:e2250647. doi: 10.1001/jamanetworkopen.2022.50647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.50647</ArticleId><ArticleId IdType="pmc">PMC9857047</ArticleId><ArticleId IdType="pubmed">36633846</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M.A., Henderson J.P., Shah P.K., Rubinstein S.M., Joyner M.J., Choueiri T.K., Flora D.B., Griffiths E.A., Gulati A.P., Hwang C., et al. COVID-19 and Cancer Consortium. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021;7:1167–1175. doi: 10.1001/jamaoncol.2021.1799. Erratum in: JAMA Oncol. 2021, 7, 1249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.1799</ArticleId><ArticleId IdType="pmc">PMC8377563</ArticleId><ArticleId IdType="pubmed">34137799</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragotakes Q., Johnson P.W., Buras M.R., Carter R.E., Joyner M.J., Bloch E., Casadevall A. Estimates of actual and potential lives saved in the United States from the COVID-19 convalescent plasma. medRxiv. 2024 doi: 10.1101/2024.05.16.24307505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.05.16.24307505</ArticleId></ArticleIdList></Reference><Reference><Citation>Istituto Superiore di Sanità  Italian Blood System 2021: Activity Data, Hemovigilance and Epidemiological Surveillance. Rappporti ISTISAN 2022; 22/25: 1-88.  [(accessed on 1 September 2024)].  Available online:  https://www.iss.it/-/rapporto-istisan-22/25-italian-blood-system-2021-activity-data-haemovigilance-and-epidemiological-surveillance.-liviana-catalano-vanessa-piccinini-ilaria-pati-francesca-masiello-francesco-barone-giuseppe-marano-simonetta-pupella-vincenzo-de-angelis.</Citation></Reference><Reference><Citation>Menichetti F., Popoli P., Puopolo M., Spila Alegiani S., Tiseo G., Bartoloni A., De Socio G.V., Luchi S., Blanc P., Puoti M., et al. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Netw. Open. 2021;4:e2136246. doi: 10.1001/jamanetworkopen.2021.36246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.36246</ArticleId><ArticleId IdType="pmc">PMC8630572</ArticleId><ArticleId IdType="pubmed">34842924</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzini P.M., Ciccone G., De Rosa F.G., Cavallo R., Ghisetti V., D’Antico S., Galassi C., Saccona F., Castiglione A., Birocco N., et al. Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: Short and long-term effects. A three-arm randomized controlled clinical trial. BMC Infect. Dis. 2022;22:879. doi: 10.1186/s12879-022-07716-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07716-5</ArticleId><ArticleId IdType="pmc">PMC9682750</ArticleId><ArticleId IdType="pubmed">36418984</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silvestro G., Marson P., La Raja M., Cattelan A.M., Guarnieri G., Monticelli J., Tiberio I., Vianello A., Gandini G., Gessoni G., et al. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry. Eur. J. Intern. Med. 2022;97:42–49. doi: 10.1016/j.ejim.2021.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.12.023</ArticleId><ArticleId IdType="pmc">PMC8710400</ArticleId><ArticleId IdType="pubmed">34980505</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini M., Glingani C., Donno G., Lucchini G., Beccaria M., Amato M., Castelli G.P., Bianciardi L., Pagani M., Ghirardini M., et al. Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience. Life. 2022;12:420. doi: 10.3390/life12030420.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12030420</ArticleId><ArticleId IdType="pmc">PMC8950373</ArticleId><ArticleId IdType="pubmed">35330170</ArticleId></ArticleIdList></Reference><Reference><Citation>Istituto Superiore di Sanità  Epidemia COVID-19. Aggiornamento Nazionale. 7 January 2022.  [(accessed on 1 September 2024)].  Available online:  https://epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_5-gennaio-2022.pdf.</Citation></Reference><Reference><Citation>Istituto Superiore di Sanità  Sorveglianza Integrata COVID-19: I Principali Dati Nazionali.  [(accessed on 30 July 2024)].  Available online:  https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati.</Citation></Reference><Reference><Citation>Arnold Egloff S.A., Junglen A., Restivo J.S., Wongskhaluang M., Martin C., Doshi P., Schlauch D., Fromell G., Sears L.E., Correll M., et al. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J. Clin. Investig. 2021;131:e151788. doi: 10.1172/JCI151788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI151788</ArticleId><ArticleId IdType="pmc">PMC8516450</ArticleId><ArticleId IdType="pubmed">34464352</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R., Pérez Marc G., Wappner D., Coviello S., Bianchi A., Braem V., Polack F.P. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N. Engl. J. Med. 2021;384:610–618. doi: 10.1056/NEJMoa2033700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2033700</ArticleId><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan D.J., Gebo K.A., Shoham S., Bloch E.M., Lau B., Shenoy A.G., Hanley D.F. Early Outpatient Treatment for COVID-19 with Convalescent Plasma. N. Engl. J. Med. 2022;386:1700–1711. doi: 10.1056/NEJMoa2119657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119657</ArticleId><ArticleId IdType="pmc">PMC9006786</ArticleId><ArticleId IdType="pubmed">35353960</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine A.C., Fukuta Y., Huaman M.A., Ou J., Meisenberg B.R., Patel B., Paxton J.H., Hanley D.F., Rijnders B.J.A., Gharbharan A., et al. Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials. Clin. Infect. Dis. 2023;76:2077–2086. doi: 10.1093/cid/ciad088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad088</ArticleId><ArticleId IdType="pmc">PMC10273382</ArticleId><ArticleId IdType="pubmed">36809473</ArticleId></ArticleIdList></Reference><Reference><Citation>McCreary E.K., Escobar Z.K., Justo J.A. Monoclonal Antibodies for the Treatment of COVID-19-Every Day You Fight Like You’re Running Out of Time. JAMA Netw. Open. 2023;6:e239702. doi: 10.1001/jamanetworkopen.2023.9702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.9702</ArticleId><ArticleId IdType="pubmed">37093604</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A., Dragotakes Q., Johnson P.W., Senefeld J.W., Klassen S.A., Wright R.S., Joyner M.J., Paneth N., Carter R.E. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. eLife. 2021;10:e69866. doi: 10.7554/eLife.69866.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.69866</ArticleId><ArticleId IdType="pmc">PMC8205484</ArticleId><ArticleId IdType="pubmed">34085928</ArticleId></ArticleIdList></Reference><Reference><Citation>Italian Medicine Agency  COVID-19: TSUNAMI Study, Plasma Does Not Reduce the Risk of Respiratory Damage or Death.  [(accessed on 8 April 2021)]; Available online:  https://www.aifa.gov.it/en/-/covid-19-studio-tsunami-il-plasma-non-riduce-il-rischio-di-peggioramento-respiratorio-o-morte.</Citation></Reference><Reference><Citation>Prati D., Fiorin F., Berti P., De Silvestro G., Accorsi P., Ostuni A. Italian Society for Transfusion Medicine and Immunohaematology (SIMTI), and the Italian Society for Haemapheresis and Cell Manipulation (SIdEM). Position paper on the use of COVID-19 convalescent plasma: An update. Blood Transfus. 2021;19:277–280. doi: 10.2450/2021.0150-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.2450/2021.0150-21</ArticleId><ArticleId IdType="pmc">PMC8297677</ArticleId><ArticleId IdType="pubmed">34059190</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Guidance Document  Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma.  [(accessed on 10 August 2024)]; Available online:  https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-investigational-and-licensed-covid-19-convalescent-plasma.</Citation></Reference><Reference><Citation>Worldometer  Italy, C.O.V.I.D. Coronavirus Statistics.  [(accessed on 9 August 2024)].  Available online:  https://www.worldometers.info/coronavirus/country/italy/</Citation></Reference><Reference><Citation>Joyner M.J., Carter R.E., Senefeld J.W., Klassen S.A., Mills J.R., Johnson P.W., Theel E.S., Wiggins C.C., Bruno K.A., Klompas A.M., et al. Convalescent Plasma Antibody Levels and the Risk of Death from COVID-19. N. Engl. J. Med. 2021;384:1015–1027. doi: 10.1056/NEJMoa2031893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031893</ArticleId><ArticleId IdType="pmc">PMC7821984</ArticleId><ArticleId IdType="pubmed">33523609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>